Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan in advanced differentiated and anaplastic thyroid cancer
2023-504898-20-00Phase 2Authorised
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Feb 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sacituzumab govitecan in thyroid neoplasm (2 cohorts), sponsored by Spanish Group of Neuroendocrine Tumors. Primary endpoint: Objective response rate (ORR). Planned start Feb 2024; status: authorised.
02
Drugs
sacituzumab govitecan
03
Conditions
thyroid neoplasm
Beyond the preview
Go deeper on 2023-504898-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504898-20-00.